Investment
Features
FeesSafety
Academy
More
Pluang+

Compare Archer Aviation Inc (ACHR) vs Ascendis Pharma A/S (ASND) Price & Performance

Archer Aviation IncTrade
Ascendis Pharma A/STrade

Price performance (Past 24H)

Key statistics

Archer Aviation Inc vs Ascendis Pharma A/S — how do they compare? Archer Aviation Inc trades at $6.27 (market cap $5.23B), while Ascendis Pharma A/S trades at $260.65 (market cap $16.67B). The key difference: Ascendis Pharma A/S is far larger — about 3.2× Archer Aviation Inc's market cap, and Ascendis Pharma A/S is trading nearer its 52-week high, Archer Aviation Inc nearer its low. Which is the better fit depends on your goals.

ACHRASND
Market Cap
$5.23B$16.67B
Sector
IndustrialsHealth
52-Week High
$13.64$277.18
52-Week Low
$4.44$189.74
Enterprise Value
$3.79B$17.04B

Aura AI Summary

Signals from Pluang's Aura AI — not financial advice

Archer Aviation Inc

Archer Aviation (ACHR) trades at $6.29, up 0.48% with strong technical momentum and bullish analyst sentiment. The company reported Q2 2026 revenue of $5 million, beating expectations by 150%, while announcing a transformative Boeing deal acquiring three businesses for a 20% equity stake. Despite negative profitability metrics and substantial cash burn, the strategic expansion into defense and autonomous aviation technology has driven recent stock appreciation.

The outlook remains speculative with significant execution risks, but strategic partnerships and regulatory progress provide potential upside. Investors face dilution concerns from the $750 million equity offering while betting on long-term commercialization of air taxi technology. The stock's valuation appears stretched with P/S ratio of 719.85, requiring successful commercialization to justify current levels.

Ascendis Pharma A/S

Ascendis Pharma (ASND) trades at $255.46, showing minimal daily movement (-0.06%). The stock maintains a bullish technical outlook with strong analyst support (92% buy ratings) and a consensus price target of $309.75, representing 21% upside potential. Recent developments include positive clinical trial updates for TransCon CNP in achondroplasia and inclusion in multiple Russell indexes, signaling growing institutional recognition. Revenue growth has been robust, increasing from $51M in 2022 to $720M in 2025, though the company remains unprofitable with a net loss of $228M in 2025.

ASND presents a growth investment opportunity with multiple product catalysts and improving financial trajectory, though significant risks remain. The company's premium valuation (P/E 29.05, P/S 15.68) reflects high growth expectations, while negative shareholder equity and substantial debt require careful monitoring. Positive cash flow generation since 2024 and upcoming regulatory milestones provide potential upside, but execution risks and clinical trial outcomes could impact shareholder value.

Returns comparison

Trailing returns across standard periods

Top news

Latest headlines on both assets

About Archer Aviation Inc

Archer Aviation develops electric vertical takeoff and landing (eVTOL) aircraft for urban air mobility. Its flagship, Midnight aircraft, is designed for air taxi services, aiming to transform urban travel with sustainable aviation.

Read more on ACHR

About Ascendis Pharma A/S

Ascendis Pharma A/S is a biopharmaceutical company. It develops prodrug therapies with profiles to address large markets with significant unmet medical needs with its Transcon technology. The firm's product pipeline includes Transcon growth hormone, Transconpeptides, Transcon PTH, Transcon CNP, and others. It operates mainly in North America, Germany, China, and Denmark and derives the majority of its revenue from China.

Read more on ASND